News
Important Only
EMERGING MARKETS-Latam currencies under pressure from firm dollar at end of rate decision-packed week
Latam stocks down 0.5%, FX off 0.8%Russian central bank holds rates at 21%Turkish assets continue to slideColombia's peso worst hit in Latam this weekBy Shashwat Chauhan March 21 (Reuters) - Most Latin American currencies slipped on Friday as the dollar remained firm, wrapping up a week packe...Reuters
Fri, Mar 21
Copper miners fall on stronger dollar
** Copper miners fall tracking price of the red metal ** Benchmark three-month copper CMCU3 on the London Metal Exchange down 0.6% to $9,877 a metric ton** Copper prices fall under pressure from a stronger dollar** U.S.-listed shares of global mining giants Rio Tinto RIO.N and BHP BHP.N drop 2.1% an...Reuters
Fri, Mar 21
Nio Earnings: What Went Wrong?
In this video, I will review Nio's (NYSE: NIO) latest earnings report and management comments about the company's future. Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of March 21, 2025. The video was pu...The Motley Fool
Fri, Mar 21
What Are the Chances That XRP Climbs to $100?
As of March 20, XRP's (CRYPTO: XRP) price is around $2.50. But under the right set of conditions, could its price ever reach $100 per coin?To figure that out, let's do a quick calculation and assess its fundamentals as well as a couple of catalysts that are in play right now.Where to invest $1,000 r...The Motley Fool
Fri, Mar 21
Chipmaker Micron's shares slump as tepid margin forecast eclipses AI prospects
March 21 (Reuters) - Micron's MU.O shares fell 8% on Friday, as its dour margin forecast took the shine off a robust quarterly revenue outlook driven by demand for its semiconductors used in artificial intelligence tasks. Micron, one of only three providers of high-bandwidth memory (HBM) chips f...Reuters
Fri, Mar 21
Allurion Technologies jumps on initial data from weight-loss device treatment
** Healthcare company Allurion Technologies' ALUR.N shares rise 50% to $3.43** Co says initial data shows patients treated with its device along with low doses of Novo Nordisk's NOVOb.CO semaglutide resulted in average total body weight loss of 20.3% and an increase of lean body mass by 15%*...Reuters
Fri, Mar 21
LIVE MARKETS-US indexes drop with outlooks weak, Fed talk uncertain
U.S. equity indexes red: Dow falls most, off ~1%Materials weakest S&P sector; Comm Svcs sole gainerEuro STOXX 600 index falls ~1%Dollar up; crude ~flat; bitcoin slips; gold off >1%U.S. 10-Year Treasury yield flat at ~4.23%Welcome to the home for real-time coverage of markets brought to you by...Reuters
Fri, Mar 21
Energy firms fall as oil prices edge lower
** S&P 500 energy index .SPNY falls 0.8% as oil prices edge lower** Brent crude futures LCOc1 down 0.4% at $71.73 per barrel; U.S. West Texas Intermediate (WTI) crude CLc1 falls 0.2% to $67.91 per barrel** Oil prices fell slightly on Friday but were headed for second consecutive weekly gain as f...Reuters
Fri, Mar 21
US STOCKS-Wall St falls on tariff woes; FedEx slides after bleak forecast
Indexes off: Dow 1.05%, S&P 500 0.87%, Nasdaq 0.79%Nike dips on bleak revenue outlookMicron falls on conservative gross margin forecast By Pranav Kashyap and Johann M Cherian March 21 (Reuters) - Wall Street's main indexes declined on Friday as investors continued to navigate the comp...Reuters
Fri, Mar 21
Carnival Corp reports results for the quarter ended February 28 - Earnings Summary
Carnival Corp CCL.N reported quarterly adjusted earnings of 13 cents per share for the quarter ended February 28, higher than the same quarter last year, when the company reported EPS of -14 cents. The mean expectation of twenty analysts for the quarter was for earnings of 2 cents per share. Wall...Reuters
Fri, Mar 21
3 Reasons to Buy Coca-Cola Stock Like There's No Tomorrow
It's not every day, or every year, that Coca-Cola (NYSE: KO) stock beats the market. In fact, it's been a rare occurrence over the past 30 years. However, it's happening now. Coca-Cola stock is up 12% this year, while the S&P 500 is down 4%.It's as good a time as ever to understand why Coca-Cola is ...The Motley Fool
Fri, Mar 21
Nike dips after bleak revenue forecast; brokerages trim PT
** Shares of sportswear giant Nike NKE.N down 7.9% at $66.19, hitting their lowest since March 2020 ** Co on Thursday warned of another quarter of sales decline, leaving some investors worried about the pace of crucial turnaround under new CEO Elliott Hill ** NKE forecast steeper-than-exp...Reuters
Fri, Mar 21
Cruise operator Carnival falls after forecasting Q2 adjusted EPS below estimate
** Shares of cruise operator Carnival Corp CCL.N down 3.5% at $20.45 in early trading** Company forecasts Q2 adjusted EPS of 22 cents, below analysts' estimate of 23 cents, according to data compiled by LSEG** Not completely immune from heightened macroeconomic and geopolitical volatility, says ...Reuters
Fri, Mar 21
Turkey ETF slumps, set for worst week since 2018 on political turmoil
** iShares MSCI Turkey ETF TUR.O drops 7.8% to $30.68, a nearly two-year low ** Fund on track for weekly losses of over 20%, set for worst week since August 2018** Slump sparked by market turmoil following Turkish authorities' detainment of Istanbul mayor Ekrem Imamoglu, President Tayyip Erdoga...Reuters
Fri, Mar 21
Snow Lake Resources gains on Trump order to boost US critical minerals production
** Uranium miner Snow Lake Resources' LITM.O shares up 18.5% to $0.71** U.S. President Donald Trump on Thursday invoked emergency powers to boost domestic production of critical minerals used widely across the economy as part of a broad effort to offset China's near-total control of the sect...Reuters
Fri, Mar 21
TOT BIOPHARM (1875.HK) Turns a Profit for the First Time, Reports 2024 Net Income of RMB 34.8M
Guru Club, March 12丨TOT BIOPHARM - B (1875.HK) announced that for the full-year results ending December 31, 2024, the Company reported better-than-expected performance, with annual revenue reaching RMB 1.098 billion, representing a 41% year-on-year increase. In 2024, it achieved a turnaround from loss to profit for the first time, posting a net profit of RMB 34.8 million. With continuously enhanced cash generating capabilities, the net cash from operating activities has been positive for three consecutive years, reaching RMB116.4 million in 2024. The CDMO (Contract Development and Manufacturing Organization) business demonstrated robust growth potential with a notable funnel effect. Leveraging its cutting-edge technology platforms to enhance front-end pipeline promotion, the Company saw a significant increase in early-stage projects. It added 58 new projects throughout the year, including 48 ADC (Antibody - Drug Conjugate) projects, bringing the total to 153 projects. Notably, it secured 2 pre-BLA (Pre-Biologics License Application) projects, bringing the total number to 8, fully demonstrating the Company's outstanding capability in late-stage CDMO commercialization projects and further strengthening its potential for future revenue expectations. The Company's service backlog on hand reached RMB 191 million, marking a 39% year-on-year growth.Widely recognized by the industry world-wide, the Company's high-standard quality management system has passed many production site inspections by relevant drug regulatory authorities and GMP compliance inspections in many countries, as well as several GMP inspections by customers and third-party consulting agencies. In 2024 alone, the Company received 38 GMP audits in total, including 7 official GMP audits (3 by foreign authorities and 4 by domestic authorities) and 2 EU QP audits (one of which was passed with zero defects). The Company also obtained GMP certificates from countries such as Colombia, Egypt, and Indonesia. Additionally, the Company obtained the Accreditation of Foreign Manufacturers by the PMDA in Japan, signifying that TOT BIOPHARM's production lines and quality system comply with Japanese pharmaceutical quality and safety standards. Furthermore, the Company assisted its customers in completing inspections by their overseas partnering multinational pharmaceutical companies and other institutions on multiple occasions, and successfully collaborated with its customers in completing the licensing with high recognition.21/03/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Fri, Mar 21
TOT BIOPHARM (1875.HK) Turns a Profit for the First Time, Reports 2024 Net Income of RMB 34.8M
Guru Club, March 12丨TOT BIOPHARM - B (1875.HK) announced that for the full-year results ending December 31, 2024, the Company reported better-than-expected performance, with annual revenue reaching RMB 1.098 billion, representing a 41% year-on-year increase. In 2024, it achieved a turnaround from loss to profit for the first time, posting a net profit of RMB 34.8 million. With continuously enhanced cash generating capabilities, the net cash from operating activities has been positive for three consecutive years, reaching RMB116.4 million in 2024. The CDMO (Contract Development and Manufacturing Organization) business demonstrated robust growth potential with a notable funnel effect. Leveraging its cutting-edge technology platforms to enhance front-end pipeline promotion, the Company saw a significant increase in early-stage projects. It added 58 new projects throughout the year, including 48 ADC (Antibody - Drug Conjugate) projects, bringing the total to 153 projects. Notably, it secured 2 pre-BLA (Pre-Biologics License Application) projects, bringing the total number to 8, fully demonstrating the Company's outstanding capability in late-stage CDMO commercialization projects and further strengthening its potential for future revenue expectations. The Company's service backlog on hand reached RMB 191 million, marking a 39% year-on-year growth.Widely recognized by the industry world-wide, the Company's high-standard quality management system has passed many production site inspections by relevant drug regulatory authorities and GMP compliance inspections in many countries, as well as several GMP inspections by customers and third-party consulting agencies. In 2024 alone, the Company received 38 GMP audits in total, including 7 official GMP audits (3 by foreign authorities and 4 by domestic authorities) and 2 EU QP audits (one of which was passed with zero defects). The Company also obtained GMP certificates from countries such as Colombia, Egypt, and Indonesia. Additionally, the Company obtained the Accreditation of Foreign Manufacturers by the PMDA in Japan, signifying that TOT BIOPHARM's production lines and quality system comply with Japanese pharmaceutical quality and safety standards. Furthermore, the Company assisted its customers in completing inspections by their overseas partnering multinational pharmaceutical companies and other institutions on multiple occasions, and successfully collaborated with its customers in completing the licensing with high recognition.21/03/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Fri, Mar 21
3 Reasons to Buy NuScale Power Stock Like There's No Tomorrow
NuScale Power (NYSE: SMR) is not an investment for the faint of heart. Indeed, it is losing money today and will probably continue to do so for at least another few years. But if you can handle a little risk, this nuclear power start-up is extremely attractive.Here are three of the primary reasons w...The Motley Fool
Fri, Mar 21
